z-logo
Premium
Clonal deleted latent membrane protein 1 variants of Epstein‐Barr virus are predominant in European extranodal NK/T lymphomas and disappear during successful treatment
Author(s) -
Halabi Mohamad Adnan,
Jaccard Arnaud,
Moulinas Rémi,
Bahri Racha,
Al Mouhammad Hazar,
Mammari Nour,
Feuillard Jean,
RangerRogez Sylvie
Publication year - 2016
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.30128
Subject(s) - virus , epstein–barr virus , virology , biology , malignancy , gene , lymphoma , sanger sequencing , herpesviridae , immunology , viral disease , dna sequencing , genetics
Extranodal natural killer/T‐cell lymphomas (NK/TL), rare in Europe, are Epstein‐Barr virus (EBV) associated lymphomas with poor outcomes. Here, we determined the virus type and analyzed the EBV latent membrane protein‐1 (LMP1) gene sequence in NK/TL from French patients. Six clones of viral LMP1 were sequenced by Sanger technology in blood from 13 patients before treatment with an l ‐asparaginase based regimen and, for 8 of them, throughout the treatment. Blood LMP1 sequences from 21 patients without any known malignancy were tested as controls. EBV Type A was identified for 11/13 patients and for all controls. Before treatment, a clonal LMP1 gene containing a 30 bp deletion (del30) was found in 46.1% of NK/TL and only in 4.8% of controls. Treatment was less effective in these patients who died more rapidly than the others. Patients with a deleted strain evolving toward a wild‐type strain during treatment reached complete remission. The LMP1 gene was sequenced by highly sensitive next‐generation sequencing technology in five NK/TL nasopharyngeal biopsies, two of them originating from the previous patients. Del30 was present in 100% of the biopsies; two viruses at least coexisted in three biopsies. These results suggest that del30 may be associated with poor prognosis NK/TL and that strain evolution could be used as a potential marker to monitor treatment.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom